• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hoffman Michael B was granted 25,001 shares, increasing direct ownership by 2% to 1,446,284 units (SEC Form 4)

    6/16/25 4:28:52 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hoffman Michael B

    (Last) (First) (Middle)
    C/O ANNOVIS BIO, INC.
    101 LINDENWOOD DR, SUITE 225

    (Street)
    MALVERN PA 19355

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Annovis Bio, Inc. [ ANVS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/13/2025 A 25,000 A $2.8 1,446,283 D
    Common Stock 06/13/2025 A 1 A $2.83 1,446,284 D
    Common Stock 223,357 I The 2018 Jane and Michael Hoffman Descendants Trust(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.
    /s/ Maria Maccecchini Attorney-in-Fact 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANVS

    DatePrice TargetRatingAnalyst
    2/10/2025Buy → Hold
    D. Boral Capital
    10/25/2024$25.00Hold → Buy
    Maxim Group
    12/29/2023$36.00Buy
    Canaccord Genuity
    7/7/2021$45.00 → $150.00Buy
    Maxim Group
    More analyst ratings

    $ANVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $69,900 worth of shares (20,000 units at $3.50), increasing direct ownership by 0.81% to 2,490,539 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/21/25 7:57:45 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $31,650 worth of shares (15,000 units at $2.11), increasing direct ownership by 0.61% to 2,470,539 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/18/25 7:44:02 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Maccecchini Maria-Luisa bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 9% to 1,212,020 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/12/25 9:19:04 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

    MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its ongoing Phase 3 AD clinical trial continues to progress with full regulatory alignment on study design, endpoints, and patient population. "We are pleased with such proactive engagement with the FD

    11/18/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

    Buntanetap significantly improves cognition in all Parkinson's patients, with those exhibiting Alzheimer's co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived tau following buntanetap treatment Findings support buntanetap's potential to address cognitive decline in Parkinson's disease, show disease-modifying efficacy, and inform future clinical development MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's

    11/17/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    SEC Filings

    View All

    SEC Form 10-Q filed by Annovis Bio Inc.

    10-Q - Annovis Bio, Inc. (0001477845) (Filer)

    11/12/25 4:16:53 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Annovis Bio, Inc. (0001477845) (Filer)

    10/28/25 5:07:47 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Annovis Bio Inc.

    424B5 - Annovis Bio, Inc. (0001477845) (Filer)

    10/28/25 2:51:58 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Annovis Bio downgraded by D. Boral Capital

    D. Boral Capital downgraded Annovis Bio from Buy to Hold

    2/10/25 8:18:59 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio upgraded by Maxim Group with a new price target

    Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

    10/25/24 7:56:01 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Annovis Bio with a new price target

    Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00

    12/29/23 7:03:31 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $69,900 worth of shares (20,000 units at $3.50), increasing direct ownership by 0.81% to 2,490,539 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/21/25 7:57:45 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $31,650 worth of shares (15,000 units at $2.11), increasing direct ownership by 0.61% to 2,470,539 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/18/25 7:44:02 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Maccecchini Maria-Luisa bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 9% to 1,212,020 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/12/25 9:19:04 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Leadership Updates

    Live Leadership Updates

    View All

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Appoints Mark Guerin as Chief Financial Officer

    MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experience and a successful track record in managing financial operations within biopharma companies. In 2013, he joined Onconova Therapeutics, now known as Traws Phar

    9/25/25 7:30:00 AM ET
    $ANVS
    $TRAW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Bio Appoints Hui Liu as Director of Biostatistics

    MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment Hui Liu as Director of Biostatistics. "Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence," said Cheng Fang, Ph.D., Senior Vice President, Research and Development. "Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move to

    4/29/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Annovis Bio Inc. (Amendment)

    SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

    11/28/23 4:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Annovis Bio Inc.

    SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

    11/8/23 7:02:36 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    Financials

    Live finance-specific insights

    View All

    Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

    Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

    10/5/21 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care